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Abstract
The lack of reliable translational procedures applicable to both patients and experimental models are a
major obstacle for the advancement of basic research as well as for the development of therapeutics.
This is particularly relevant to neurodegenerative disorders such as AD (Alzheimer’s disease), where the
predictive validity of animal models and procedures applied preclinically have met with little success. Two
approaches available for human diagnostics are currently experiencing major advancements in preclinical
research: in vivo imaging using MRI (magnetic resonance imaging) or PET (positron-emission tomography)
and recordings of brain electrical activity via surface EEG (electroencephalogram). The present paper reviews
the results obtained so far in rodent AD models, and summarizes advantages and disadvantages of such
procedures.
Introduction
Translational research requires biomarkers that (i) can be
obtained both in clinic and preclinic; (ii) are reproducible,
graded and sensitive (>80%) indicators of the individual’s
health status; and (iii) are disease specific (>80%).
Additionally, it is desirable that methods of biomarker
quantification are affordable, non-invasive or at least low risk,
and samples are easily accessible and quantifiable. Disease
biomarkers are classified as antecedent (predicting the risk
of developing a disease), diagnostic (identifying an existing
condition) or prognostic (detecting the course of a disease
and therapeutic success). The mutual dependence between
efficient translational research, early diagnosis and treatment
must be recognized, alongwith their implications for patients:
treatment benefits would be greatest in early stages of the
disease, but reliable detection is ethically difficult to justify if
no therapy can be offered.
Despite its high prevalence, reliable translational
biomarkers for dementia, and AD (Alzheimer’s disease) in
particular, are still elusive. In humans, cognitive testing is
commonly administered (e.g. mini mental state examination),
but cannot reliably identify prodromal stages and provide
prognostic value. Importantly, tasks probing for episodic
memory, a cognitive function most characteristically
diminished in AD patients, have proven difficult to
implement in rodents [1]. Thus forward translation (from
animal to patient) cannot be readily achieved. Advancements
are further complicated by the non-standardized,
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idiosyncratic approaches between laboratories with regard to
both choice of animalmodels (see below) and paradigms used.
For AD, current biomarker research focuses on molecules
identifiable in blood (plasma) or cerebrospinal fluid [2],
by and large those related to the main risk genes, i.e.
APP (amyloid precursor protein), microtubule-associated
protein tau, presenilin and apolipoprotein E [3]. To date,
however, no single parameter reliably serves as a prognostic
or diagnostic marker, and even combinational approaches
have insufficient sensitivity, specificity and reproducibility.
The hunt for disease-specific biomarkers thus now includes
genomic and proteomic analyses, as well as large-scale
neuroimaging initiatives such as the multi-centre ADNI
(Alzheimer’s disease neuroimaging initiative, [4]) which if
successful hopes to back-translate results to the preclinic.
Animal models
In its traditional form, effective translational research and
treatment development hinge on experimental models that
reliably mimic at least some aspects of the disease under
scrutiny (‘face validity’), and allow assessments of potential
treatments that can be brought forward to the clinic
(‘predictive validity’). A variety of vertebrate and invertebrate
experimental models exist that mimic some aspects of AD
pathology by overexpression of APP and/or tau [5,6].
Human, mutated APP-expressing mice show heightened
levels of βA (β-amyloid) protein, plaque-like depositions,
inflammation and occasionally synapse reduction and
dystrophic neurites. Deficits in learning and memory are
reported, but are not specific for domains typically impaired
in AD. Early tau-based models, on the other hand, generated
by introduction of familial mutations associated with
frontotemporal dementia [7,8], often presented with severe
sensory-motor deficits due to wide-spread tau pathology
in motor areas, limiting the use of these rodent models.
Generation of advanced, bi- or tri-genic mice overexpressing
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both APP, tau and/or PS1 transgenes induced accelerated and
more aggressive brain pathology [9,10] reminiscent of late-
stage AD. A clear mismatch with familial AD patients is the
required hyperexpression of transgenes in rodents to achieve
plaque and tangle-like pathologies [6]. Such expression rates
cause histopathological changes in young adults (3–6months,
seeTable 1), useful for quantificationof plaque/tangle burden.
Animals, however, are often developmentally affected and
devoid of a slow progression into prodromal AD/mild
cognitive impairment, which would be the desired time point
for dementia classification and therapeutic intervention.More
importantly, aggregated βA/tau and cognitive decline do not
correlate in many mouse models. Instead, cognitive deficits
develop in parallel with intracellular βA, prior to extracellular
plaque formation [9,10], implying soluble protein as the
cause of neuronal malfunction and toxicity [11]. Equally, a
significant proportion of elderly people have βAdeposits but
are not demented; whereas some AD patients present with
severely impaired cognition but relatively few plaques. Thus
cytosolic prefibrillary βAmono- or oligo-mers are sufficient
for early pathological events [12,13]. Similarly, oligomeric
tau proteins confer higher toxicity than fibrils and tangles
(e.g. [14]) and granular oligomers are already present in AD
patients at Braak stage 0; these intensify progressively and are
inducible in transgenic animal models and cell culture (e.g.
[15]).
Most mouse models of AD tested to date were created
by pronuclear injection of mutant transgenic material under
regulatory elements driving strong overexpression. As a
corollary, it proved difficult to avoid compensatory processes
(genetically/physiologically), a random number of (unstable)
insertion sites with uncertainties of gene dosing and location,
or making transgene expression region-, cell-type- and age-
specific [16]. To avoid such problems, better regulated
transgenic models are now emerging, for example, via
selective expression of intracellular APP [13] or by inducible
suppression of tau transgenes [17]. To model both APP-
and tau-related pathologies in a controlled manner, we have
recently developed a knock-in AD mouse (termed PLB1),
which carries single-copy-mutated human APP (Swedish
and London) and human tau (301L/406W) constructs. Both
transgenes were fused and expressed under the control of
themouseαCaMKII (α-Ca2+/ calmodulin-dependent protein
kinase) promoter [18] to ascertain postnatal forebrain and
neuron specificity of APP and tau expression. In addition,
cross breeding with an existing (asymptomatic) PS1 line
[19] resulted in PLB1Triple mice [20], which presented with
an age-related pathology of intraneuronal amyloid and
hyperphosphorylated tau accumulation in hippocampus and
cortex from 6 months of age.
In vivo FDG (2-[18F]ﬂuoro-2-deoxy-
d-glucose)–PET (positron-emission
tomography) imaging as an emerging
translational tool
Functional neuroimaging is now routinely applied in clinical
diagnosis and great strides are being made to implement
the technique as a modern translational tool in drug
discovery. Although MRI (magnetic resonance imaging) is
most widely used, others including PET, photon emission
tomography, and dual-modality imaging (e.g. MRI/PET)
have made considerable progress [4,21]. They provide high
spatial resolution of altered neural activity during resting
or event-related activation. In patients, amyloid tracers
such as [11C]PIB (Pittsburgh compound B) as well as
[18F]flobetapir (AV-45) have enabled labelling of aggregated
βA and provide a functional index for plaque development,
but at the same time showed high levels of non-specific
white matter retention and only detect grey matter plaque
load, thus lacking sensitivity for early stages of AD (see
also comments above regarding the relevance of plaque
load as a biomarker in humans). Unclear is also the
observation that PIB failed to detect plaques in high APP
expression murine models ([22], but see [23]), for which
conformational differences in fibrillary proteins have been
advocated. Novel tracers may achieve better results (e.g.
[3H]AZD2184; [24]), but have not yet been tested with
in vivo imaging.
In comparison, metabolic imaging with radio-labelled
FDG used as a standard in cancer diagnosis, lacks the desired
disease specificity, but regional metabolic patterns enable its
use as a diagnostic tool in CNS (central nervous system)
disorders, and it is suitable and directly translatable for
experimental purposes, where disease-specific models are
available, thus not requiring specific ligands.
Advantages of in vivo FDG–PET imaging comprise its
non-invasive nature, provision of physiological/functional
information, and the possibility for repeat scans enabling
longitudinal studies and within-subject comparisons. Disad-
vantages and challenges must however also be recognized:
the size of the mouse brain (∼3000 times smaller than human
brain) makes accurate registration essential and, together
with the lack of anatomical detail and limits of resolution,
region-specific effects difficult to decipher. For animal
studies, anaesthesia is generally administered during image
acquisition, therefore precluding the recording of functional
information arising from a behavioural context (e.g. during
cognitive task performance). Devices such as the ‘RatCap’
aim at addressing this issue [25], but are not providing genuine
unrestricted conditions and are not suitable for mice.
Sensitive, disease-specific PET signatures from patients
that map on to animals still need to be determined and
validated, notwithstanding the high costs associated with
purchase and maintenance of suitable facilities, and image
analyses that require specialist knowledge and are at present
not standardized. The application of an a priori defined seed
voxel analysis provides a powerful tool, but exploratory
or data-driven approaches such as independent or principal
component analysis may reveal changes in metabolism that
are not immediately intuitive [26]. For example, areas of
apparent hypermetabolism in the diseased brain can be
the results of the normalization process (e.g. compared
with whole brain or cerebellum), metabolic phenotypes can
emerge as the consequence of confounding factors (e.g. the
C©The Authors Journal compilation C©2011 Biochemical Society
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Table 1 Overview of FDG-PET, EEG and sleep phenotypes reported in rodent AD models
Unless indicated otherwise, models are transgenic mice. No studies based on these technologies have yet been published in tau models. PS, presenilin; ICV, intracerebroventricular; NA, not analysed.
Histopathological Cognitive Increased Sleep EEG power FDG-PET
Model Transgenes Procedure phenotype phenotype wakefulness fragmentation spectra shifts phenotype Reference(s)
Tg2576 APPswe
(KM670/
671NL)
Pronuclear, random
integration
Onset: ∼9 months,
moderate, no tau
pathology, no cell loss
Cognitive deﬁcit from ∼9
months
No (reduced
REM)
No Yes, but not
AD-like
No phenotype or
hyper-metabolism
only in young mice
[30,31,40,41,43]
PSAPP (Tg2576×PS1) APPswe
PS1M146L
Pronuclear, random
integration
Early onset (2–3 months),
very aggressive, no
tau pathology, no cell
loss
Variable, non-progressive Yes (young only) No Yes, but not
AD-like
Central
hypo-metabolism,
ventral
hyper-metabolism,
autoradiography:
global and early
hypo-metabolism
Present paper;
[44]
APP×PSEN APPswe
PS1A246E
Pronuclear, random
integration
Onset: ∼6 months,
aggressive, no tau
pathology, no cell loss
Variable, progressive Yes No Yes, but not
AD-like and not
age-dependent
No Present paper;
[39,45]
APP×PSEN APPswe&lon
PS1M146V
Pronuclear, random
integration
Early onset (2–3 months) Cognitive deﬁcit from ∼10
months
NA NA NA No PET study,
three-dimensional
autoradiography:
hyper- and
hypo-metabolism
detected in
AD-relevant areas
[46]
PDAPP APP (V717F) Pronuclear, random
integration
Onset: ∼6 months,
aggressive, no tau
pathology, cell loss
from 3 months?
Early onset (3 months),
variable,
non-progressive
Yes (only dark
period)
Yes (REM) NA No PET study,
autoradiography:
early
hypo-metabolism (2
months)
[27,47]
3×Tg APPswe
Tau301L
PS1M146V
Pronuclear (APP and
tau) and knock-in
(PS1)
Onset: amyloid ∼6
months, tau: delayed,
aggressive, no cell loss
Early onset (pre-plaque),
progressive
Some circadian
abnormalities
NA NA No PET study,
autoradiography:
global and early
hypometabolism (2
months)
[29,48]
Aβ25–35 infused rats NA ICV infusions NA Spatial memory impaired
1 month post-perfusion
NA NA Yes NA [49]
PLB1Triple APPswe&lon
Tau301L/406W
PS1A246E
Knock-in, targeted
insertion
Onset: ∼6 months, subtle
amyloid and tau
pathol, no cell loss
Moderate, progressive Yes Yes (NREM) Yes Onset: 6 months,
cortical
hypometabolism,
ventral
hypermetabolism
Present paper;
[50]
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Figure 1 FDG–PET phenotypes in (A) PSAPP (14 months) and
(B) PLB1Triple (18 months) mice
Group comparisons with age-matched wild-type controls are depicted for
lateral (L, lateral; A, anterior; H, horizontal) views of three-dimensional
images; areas of signiﬁcant increase (red) and decrease (blue) are
illustrated based on SPM (statistical parametric mapping) at P < 0.01.
A surface render of a CT (computed tomography) image provides the
anatomical reference. Cortical areas (indicated by a yellow ellipse) are
most affected by amyloid plaque build-up, but appear metabolically
unchanged in PSAPP mice while PLB1Triple mice display cortical
hypometabolism.
transgene or genetic background may have affected general
growth [27]), changes can occur as a result of inflammation
and metabolic activity of glia [28] or display compensatory
neuronal activity.
In a recent pilot study, we compared FDG–PET pheno-
types in cohorts of three young (4–5months) and aged (17–10
months) transgenic mice (PSAPP, APP/PS1 and PLB1Triple).
Data were pooled for each genotype, and compared with age-
matched wild-type litter mates using voxel-based statistical
parametric mapping (two-step analyses, voxel threshold:
P< 0.01, cluster threshold: P< 0.05). Parametric maps of
changes in FDG uptake displayed significant differences
(hypermetabolism: red, hypometabolism: blue) between
genotypes (Figure 1 and Table 1). No significant differences
were detected in any of the young mice and in aged APP/PS1
mice, but metabolic activity was reliably compromised in
both aged PSAPP and PLB1Triple transgenic mice cf. controls.
Interestingly, cortical areas, severely affected by plaque load,
showed no evidence of metabolic change in PSAPP mice,
while PLB1Triple mice displayed cortical hypometabolism and
basal hypermetabolism.
Compared with data from other AD models acquired
by FDG-based autoradiography (see Table 1), metabolic
changes were, for example, also reported in the 3×Tg mouse
[29], but AD-relevant brain region specificity was poor.
The observation that more aggressive AD pathology led
to impaired metabolism at a preplaque age of 2 months in
PDAPP mice [27] may be interpreted as a developmental
phenotype and, owing to the poor overall health of such
models, also indicated by lower body weights intrinsic to
these lines, and not as an age-related decline in cognition and
corresponding brain activation. As for the limited number
of in vivo FDG–PET studies available to date (Table 1),
APP overexpressing mice have so far not presented with
AD-like FDG–PET phenotypes [30,31]. For example, FDG–
PET studies conducted in Tg2576 mice identified areas of
hypermetabolism in young adult (7-month-old) transgenic
mice cf. wild-types, but no differences were revealed in older
mice [31].
Overall, altered glucose metabolism does not appear to
correlate with plaque load, this is in agreement with evidence
from a number of studies negating plaques as reliable
biomarker linked with cognition (see above). Nevertheless,
PLB1Triple mice displayed a robust age-dependent, bi-
directional change in metabolic activity compared with their
wild-type counterparts. With respect to transgene expression
in AD-relevant brain regions, the observed hypometabolism
goes some way in matching the human endophenotype.
EEG (electroencephalogram), sleep and
circadian activity
In contrast with neuroimaging, EEG has been conducted for
over 100 years and serves as a diagnostic tool for a number
of conditions, such as sleep disorders and epilepsy [32].
EEG is a relatively inexpensive procedure and available to
smaller clinics and research groups, making it an attractive
diagnostic and research tool. Superior to imaging is the high
temporal resolution, since sample rates in the kHz range can
be achieved. Some spatial information is provided bymultiple
recordings sites, but activity is captured from superficial
areas only. As for imaging, the complexity of data analyses
using linear and non-linear algorithms created uncertainties
vis-a`-vis reliability of results, but more fully automated and
standardized procedures are currently in development, aided
by internet platforms and novel computational tools.
EEG and sleep research complement each other, as typical
EEG signatures are highly dependent on vigilance stages,
motor activity and sleep phases, and thus used in sleep
research and clinics. Sleep phenotypes are determined by
circadian and ultradian cycles of three main vigilance stages:
wakefulness, paradoxical or REM (rapid eye movement)
sleep, and slow wave or NREM (non-REM) sleep [33]. Sleep
function remains elusive despite an increasing comprehension
of cellular and physiological processes underlying both the
generation andmodulation of sleep stages and its involvement
in memory consolidation [34]. Sleep disturbances and altered
circadian/ultradian patterns (such as frequent daytime naps)
are commonly observed in AD patients, and positively
correlate with the EEG power spectrum shift to lower
frequencies, and incoherent fast rhythms, likely to arise
from failing cholinergic transmission [35]. Recent evidence
suggests that sleep disturbances precede overt degenerative
events in AD [36], and EEG could be a more sensitive
diagnostic tool for early degeneration than cognition
[37]. Novel approaches in qEEG (quantitative EEG) have
high prediction accuracy (95%) for conversion from mild
cognitive impairment to dementia [38].
By comparison, preclinical studies applying qEEG have
so far rarely been conducted. We have recently performed a
comprehensive analysis of sleep patterns, vigilance staging
C©The Authors Journal compilation C©2011 Biochemical Society
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Figure 2 Changes in wakefulness and EEG spectra as a prodromal markers in young-adult transgenic compared with wild-type mice
(A) A trend for increased wakefulness (illustrated as percentage of time, during light phase) was observed in PSAPP and
APP/PS1 mice, but only reached signiﬁcance in PLB1Triple mice. (B) Normalized power spectra (δ–α bands) recorded during
wakefulness from PSAPP, PLB1Triple (n = 5 per group) and APP/PS1 mice [39] at 4–5 months of age, recorded above the
parietal cortex. A loss of δ power was observed in the aggressively overexpressing models, an AD-like shift towards lower
frequencies only occurred in PLB1 mice. WT, wild-type controls; TG, transgenic mice.
and qEEG changes at rest in APP/PS1-overexpressing
mice (Table 1) using wireless microchip technologies and
observed elevated wakefulness pre-plaque, and a genotype-
and age-dependent decline in low and an increase in high-
frequency spectral EEG power [39]. Other plaque-bearing
mice (Tg2576) also presented with reduced REM sleep at 6
and 12 months, but sleep fragmentation and AD-like shifts
in spectral power (recorded above the parietal cortex) have
so far only been observed in a pilot study conducted in our
PLB1Triple mice [40–42] (see Figure 2 andTable 1), and showed
congruency with FDG hypometabolism maps (Figure 1).
Intriguing is the vast difference in experimental acquisition
time (minutes in PET, 24 h in qEEG), lending compelling
support to the notion that PLB1Triple mice express robust
translational biomarkers accessible to both metabolic and
physiological imaging.
What remains to be determined is whether shifts in
spectral power and altered vigilance staging correlate with
cognition and histopathology in PLB1 mice and is sensitive
to therapeutic intervention. Initial data indicate that they
precede the emergence of cognitive decline by severalmonths,
and thus may serve as convenient and reliable prognostic
biomarkers that enable accurate prediction of onset and
monitoring of progression of AD-like symptomatology [32].
Conclusions
Preclinical in vivo imaging is still in its infancy and
lags behind its clinical counterpart. However, growing
demand for translational applications in conjunction with
advancements in imaging technology and tracer development
make this approach a prime candidate for future research. In
comparison, EEG recordings have a long-standing history in
clinical diagnosis and are more readily available. This field
is currently experiencing a revival in translational research,
due to novel recording devices and advanced computational
abilities. It will be important in the near future to seek
harmonization of recording and analysis techniques between
human and rodent/monkey applications to foster a more
direct comparison between the different disciplines.
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